Loading…
Global Longlife Hospital and Research (BSE 543520)₹14.53+0.55%Hospital
In the Mar 2026 quarter (standalone), Global Longlife Hospital and Research reported sales of ₹0 Cr and net profit of −₹0.39 Cr. For the year to Mar 2026, sales were ₹0 Cr and net profit −₹1.71 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 11.67 | 12.30 | 1.17 | 0.57 | 0.00 | 0.00 | 0.00 |
| Expenses | 9.46 | 9.64 | 4.21 | 4.40 | 0.36 | 0.61 | 0.41 |
| Operating Profit | 2.25 | 2.70 | −3.01 | −3.80 | −0.34 | −0.59 | −0.39 |
| OPM % | 19.3% | 22.0% | −256.0% | −656.9% | — | — | — |
| Other Income | 0.16 | 0.01 | 0.03 | 5.67 | −0.66 | 0.00 | 0.00 |
| Interest | 0.19 | 0.40 | 0.35 | 0.27 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.60 | 0.62 | 0.65 | 0.49 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.65 | 1.72 | −3.99 | 1.13 | −1.03 | −0.60 | −0.41 |
| Tax % | 35.4% | 39.8% | −19.1% | −11.6% | 3.0% | 123.8% | 0.0% |
| Net Profit | 1.06 | 1.02 | −3.21 | 1.23 | −1.03 | −1.31 | −0.39 |
| EPS (Rs) | 1.03 | 0.99 | −3.08 | 1.19 | −1.00 | −1.27 | −0.39 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 33.33 | 33.21 | 32.61 | 32.36 | 23.32 | 13.42 | 0.30 | 0.00 |
| Expenses | 26.68 | 29.97 | 27.34 | 24.18 | 19.35 | 13.72 | 4.46 | 1.01 |
| Operating Profit | 6.81 | 3.43 | 5.43 | 8.29 | 4.07 | −0.21 | −4.13 | −0.99 |
| OPM % | 20.4% | 10.3% | 16.6% | 25.6% | 17.4% | −1.6% | −1,335.5% | — |
| Other Income | 0.07 | 0.02 | 0.05 | 0.16 | 0.23 | 0.00 | 5.00 | 0.00 |
| Interest | 2.06 | 2.40 | 2.43 | 1.61 | 0.44 | 0.79 | 0.29 | 0.00 |
| Depreciation | 2.16 | 2.14 | 1.32 | 1.15 | 1.18 | 1.26 | 0.49 | 0.00 |
| Profit before tax | 2.70 | −1.08 | 1.76 | 5.73 | 2.71 | −2.28 | 0.11 | −1.00 |
| Tax % | 49.1% | −18.7% | −16.6% | 37.3% | 32.6% | −3.5% | −100.0% | 73.7% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.01 | 0.00 |
| Net Profit | 1.35 | −0.85 | 2.04 | 3.56 | 1.82 | −2.18 | 0.19 | −1.71 |
| EPS (Rs) | 1.93 | −1.24 | 2.94 | 5.11 | 1.75 | −2.10 | 0.20 | −1.65 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 6.99 | 6.99 | 10.51 | 10.50 | 10.52 | 10.51 |
| Reserves | 5.34 | 4.49 | 6.67 | 9.97 | 53.83 | 15.45 | 16.32 | 13.27 |
| Borrowings | 27.24 | 23.56 | 17.08 | 8.70 | 9.32 | 12.76 | 0.00 | 0.00 |
| Other Liabilities | 3.79 | 6.95 | 6.09 | 8.36 | 2.37 | 3.08 | 0.06 | 0.01 |
| Total Liabilities | 43.37 | 42.00 | 36.83 | 34.02 | 76.03 | 41.79 | 26.90 | 23.79 |
| Fixed Assets | 20.18 | 18.74 | 17.47 | 16.72 | 16.53 | 17.28 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 1.04 | 0.00 | 0.00 | 0.00 |
| Investments | 0.11 | 0.11 | 0.48 | 0.11 | 0.11 | 0.04 | 0.04 | 0.00 |
| Other Assets | 23.08 | 23.15 | 18.88 | 17.19 | 58.35 | 24.47 | 26.86 | 23.79 |
| Inventories | 2.03 | 2.20 | 0.82 | 0.89 | 0.83 | 0.45 | 0.00 | 0.00 |
| Trade receivables | 8.67 | 6.25 | 7.82 | 8.89 | 9.67 | 1.94 | 0.31 | 0.22 |
| Cash & equivalents | 0.47 | 1.30 | 0.45 | 0.23 | 3.61 | 0.38 | 21.51 | 17.01 |
| Total Assets | 43.37 | 42.00 | 36.83 | 34.02 | 76.03 | 41.79 | 26.90 | 23.79 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 5.38 | 3.89 | 6.86 | 9.40 | −40.31 | −5.05 | 12.28 | −4.49 |
| Cash from investing activity | −0.32 | −0.03 | 0.01 | 0.00 | −1.89 | −0.81 | 21.72 | 0.03 |
| Cash from financing activity | −4.78 | −3.06 | −7.23 | −9.67 | 45.78 | 2.68 | −13.04 | 0.00 |
| Net cash flow | 0.32 | 0.82 | −0.32 | −0.23 | 3.39 | −3.23 | 21.12 | −4.46 |
| Capex | 0.41 | 0.12 | 0.05 | 0.49 | 2.01 | 1.06 | 0.08 | 0.00 |
| Free cash flow | 4.99 | 3.78 | 6.83 | 8.95 | −42.35 | −6.09 | 33.38 | −4.50 |
| CFO / OP % | 79.0% | 113.0% | 126.0% | 105.0% | −960.0% | 2,259.0% | −304.0% | 401.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 95 | 69 | 88 | 100 | 151 | 53 | 377 | — |
| Inventory days | 170 | 159 | 35 | 90 | 70 | 133 | 0 | — |
| Days payable | 229 | 391 | 138 | 432 | 109 | 765 | — | — |
| Cash conversion cycle | 33 | −166 | −18 | −245 | 109 | −582 | 376 | — |
| Working capital days | 19 | 12 | 7 | −30 | 345 | −238 | 1,283 | — |
| ROCE % | — | 3.8% | 12.8% | 26.2% | 6.3% | −2.5% | −13.7% | −3.9% |
For the Mar 2026 quarter, Global Longlife Hospital and Research reported sales of ₹0 Cr and net profit of −₹0.39 Cr.
Global Longlife Hospital and Research's sales for the year to Mar 2026 were ₹0 Cr.
Net profit for the year to Mar 2026 was −₹1.71 Cr. Earnings per share over the same trailing period were ₹−1.65.
Global Longlife Hospital and Research reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹17.01 Cr.
Cash from operations was −₹4.49 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹4.50 Cr.